The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.
Bosn J Basic Med Sci. 2022 Jun 1;22(3):366-373. doi: 10.17305/bjbms.2021.7082.
The first-generation SARS-CoV-2 vaccines have played a significant role in controlling the COVID-19 pandemic, preventing severe diseases, and reducing mortality. However, the continuous emergence of SARS-CoV-2 variants, the persistence of breakthrough infections, and the seemingly rapid decline in the protective efficacy of SARS-CoV-2 vaccines have presented additional challenges for the next phase. There is an urgent need to confirm the necessity of further booster vaccination and combination vaccine approaches. This paper summarizes the latest literature on SARS-CoV-2 variants and vaccine effectiveness and concludes that it is essential to implement booster immunization strategies. Priority should be given to high-risk groups, the elderly, and immunocompromised people. In addition, heterologous vaccination has a longer duration of effect and a broader spectrum than homologous vaccination, making it more conducive to managing the immune escape of SARS-CoV-2 variants.
第一代 SARS-CoV-2 疫苗在控制 COVID-19 大流行、预防重症和降低死亡率方面发挥了重要作用。然而,SARS-CoV-2 变体的持续出现、突破性感染的持续存在以及 SARS-CoV-2 疫苗保护效力的明显快速下降,给下一阶段带来了额外的挑战。迫切需要确认进一步加强免疫接种和组合疫苗方法的必要性。本文总结了 SARS-CoV-2 变体和疫苗效力的最新文献,得出实施加强免疫策略至关重要的结论。应优先考虑高危人群、老年人和免疫功能低下者。此外,异源疫苗接种比同源疫苗接种具有更长的作用持续时间和更广泛的谱,更有利于管理 SARS-CoV-2 变体的免疫逃逸。